Category 9
Clinical-Trial Evidence and Evidence Grading
10 topics planned. Each topic is published as a Professional and Patient edition only after explicit author approval.
- Approved
- · Discovery
- · Proof of concept
- · Animal studies
- · Toxicology
- · Phase 1
- · Phase 2
- · Phase 3
- · Regulatory review
- · Postmarketing surveillance
- Approved
- · In-vitro models
- · Organoids
- · Small-animal models
- · Large-animal models
- · Disease-model validity
- · Reproducibility
- · Translation failures
- 9.3Trial designApproved
- · Randomization
- · Allocation concealment
- · Blinding
- · Placebo controls
- · Active controls
- · Sham procedures
- · Multicenter trials
- Approved
- · Eligibility criteria
- · Disease severity
- · Prior treatment
- · Comorbidities
- · Age
- · Sex
- · Race and ethnicity
- · Generalizability
- 9.5OutcomesApproved
- · Safety endpoints
- · Biomarkers
- · Imaging
- · Functional outcomes
- · Patient-reported outcomes
- · Quality of life
- · Survival
- · Clinically meaningful differences
- Approved
- · Sample size
- · Statistical power
- · Confidence intervals
- · Multiple comparisons
- · Missing data
- · Subgroup analysis
- · Intention-to-treat analysis
- Approved
- · Selection bias
- · Performance bias
- · Detection bias
- · Attrition bias
- · Selective reporting
- · Sponsorship bias
- · Publication bias
- Approved
- · Case reports
- · Case series
- · Observational studies
- · Controlled trials
- · Randomized trials
- · Systematic reviews
- · Meta-analyses
- · Guidelines
- Approved
- · Certainty of evidence
- · Magnitude of effect
- · Consistency
- · Directness
- · Precision
- · Risk-benefit balance
- Approved
- · Registration number
- · Sponsor
- · Study phase
- · Recruitment status
- · Primary endpoint
- · Results posting
- · IND claims
- · Why registration does not equal endorsement